Bonus BioGroup
Press Room

Monday, 06 January 2014 07:41

Harvard-MIT Director of Biomedical Engineering Center to Join Bonus BioGroup's Scientific Team

Rate this item
(0 votes)

Harvard-MIT Director of Biomedical Engineering Center to Join Bonus BioGroup's Scientific Team

logo4footerBonus BioGroup announces today the establishment of an agreement with Professor Elazer Edelman, M.D., Ph.D., according to which he will join the worldly renowned scientific team advising the company on product development and promoting its clinical goals. 

Professor Edelman is a Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston. Prof. Edelman directs the Harvard-MIT Biomedical Engineering Center (BMEC), operating under the Harvard-MIT Health Sciences and Technology Department, and the Edelman Lab.

Additionally, Prof. Edelman is an advisor to major American investment bodies and multinational companies, and has vast connections in the American Biotech industry.

Prof. Edelman and his laboratory have an international reputation in leading breakthrough medicine and vascular biology discoveries, from research and development to regulatory and production, including cell-based products, while applying tissue engineering, controlled drug delivery and biotechnology principals. His work has left a significant mark on biotechnology research and industry.

Dr. Shai Meretzki, CEO of Bonus BioGroup, says: "the joining of such an internationally renowned expert is an acknowledgment of the breakthrough achieved by Bonus' innovative technology, and is a vote of confidence in the company's development and commercial capabilities. We are certain Prof. Edelman's contribution to the company will be significant".

Professor Edelman's joining Bonus' leading scientific team further expands the collaboration with him, which began in a research agreement between Bonus Cellora Ltd., a fully owned subsidiary of Bonus BioGroup, and MIT, for the development of a new shelf product in the field of cellular medicine. The new product is designated for regeneration and renewal of damaged human tissue, in a combined tissue- and material engineering technology, and is simultaneously developed at MIT and Bonus BioGroup's development center in Haifa based on shared expertise and collaboration between MIT and the company.

To the company's best knowledge, in 2004, Prof. Edelman had established, along with Prof. Langer, the regenerative medicine company Pervasis Therapeutics, which had developed VascuGel, a gel-based treatment for blood vessels repair and improvement in patients with end-stage renal disease. Pervasis Therapeutics was acquired, in April 2012, while in Phase II clinical trial, by Irish biopharmaceutical company Shire PLC (LSE: SHP, NASDAQ: SHPGY), in a deal reportedly worth up to $200 million.

Bonus BioGroup seeks to further establish its technological foundation by leveraging the abilities the scientists employed at its R&D center, and further expand it by acquiring new technologies and/or exclusive rights for existing technology usage, as well as joint R&D collaboration with leading researchers in tissue engineering and overlapping fields.

Read 1436 times Last modified on Tuesday, 11 December 2018 08:49

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy | Login        

© 2021 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.